A PYMNTS Company

US: “Pharma Bro” Shkreli sued for monopoly on kidney drug

By  |  October 25, 2018
US: “Pharma Bro” Shkreli sued for monopoly on kidney drug

Retrophin and its former CEO “Pharma Bro” Martin Shkreli are facing claims by a rival drug company for monopolizing the market for Thiola, the only drug approved to treat a genetic disease that results in recurring kidney stones.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Spring Pharmaceuticals filed the lawsuit on October 24 in the US District Court for the Eastern District of Pennsylvania seeking treble damages and a permanent injunction against Retrophin, Shkreli, Mission Pharmacal, and Alamo Pharma Services.

    Full Content: Law 360

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.